



## TRANSPLANT GENOMICS LAUNCHES **OMNIGRAF™**, THE ONLY COMBINATION BIOMARKER PANEL THAT PROVIDES THE EARLIEST INDICATION OF REJECTION IN KIDNEY TRANSPLANT RECIPIENTS

*Provides significantly higher positive predictive value (PPV) and negative predictive value (NPV) than any other kidney rejection assays (or tests) on the market.*

**27 September 2021**

Transplant Genomics (“TGI”), the transplant rejection diagnostics company committed to improving organ transplant outcomes worldwide, is pleased to introduce **OmniGraf™**, which combines the **TruGraf®** blood gene expression test and **Viracor TRAC®** donor-derived cell-free DNA assays. For renal transplant recipients, **OmniGraf™** Kidney represents the first diagnostic tool that combines cell free DNA and gene expression data. When combined with TGI’s proprietary technology and machine learning, the test offers patients the earliest and most accurate view of kidney transplant rejection.

Through gene expression from **TruGraf®** and the donor-derived cell-free DNA of the **Viracor TRAC®** test, **OmniGraf™** Kidney provides a comprehensive view of both subclinical acute rejection and clinical acute rejection with the highest positive predictive value (PPV) and negative predictive value (NPV) available in a diagnostic panel. **OmniGraf™** requires 6 milliliters (mL) of blood, which can be obtained via a routine phlebotomy draw, greatly simplifying sample collection and logistics.

Commenting on the collaboration, Eurofins CEO, Dr. Gilles Martin; “We are very pleased to have collaborated with Northwestern University on this highly innovative test which will facilitate speed and accuracy in rejection detection, and, critically, improve patient outcomes. This partnership highlights the Group’s commitment to innovation and the advancement of science to improve the health and safety of our world. We look forward to the roll out of this test to medical institutions globally, so transplant patients and healthcare professionals can benefit from strengthened insights to inform treatment decisions.”

“It was an honor to collaborate with Eurofins Transplant Genomics, Inc., a pioneer and leader in biomarker tests for transplant recipients,” said Dr. John Friedewald from Northwestern University. “**OmniGraf™** Kidney is a revolutionary test that allows transplant centers, the community of nephrologists, and transplant patients to make informed and more frequent decisions about managing immunosuppression and kidney transplant health. I see this as a major advance in enhancing patient care and bringing hope and peace of mind to our patients.”

**OmniGraf™** is a trademark of Transplant Genomics, Inc.

**TruGraf®** and **TRAC®** are registered trademarks of Transplant Genomics, Inc.

## Notes to Editors:

For more information, please visit [www.eurofins.com](http://www.eurofins.com) or contact:

Investor Relations  
Eurofins Scientific SE  
Phone: +32 2 766 1620  
E-mail: [ir@eurofins.com](mailto:ir@eurofins.com)

## About Eurofins – the global leader in bio-analysis

Eurofins is Testing for Life. Eurofins is the global leader in food, environment, pharmaceutical and cosmetic product testing and in agrosience Contract Research Organisation services. Eurofins is one of the market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, advanced material sciences and in the support of clinical studies, as well as having an emerging global presence in Contract Development and Manufacturing Organisations. The Group also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products.

With 55,000 staff across a decentralised and entrepreneurial network of 900 laboratories in over 50 countries, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services and in-vitro diagnostic products.

The Group's objective is to provide its customers with high-quality services, innovative solutions and accurate results on time. Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the increasing demands of regulatory authorities as well as the requirements of healthcare practitioners around the world.

In 2020, Eurofins reacted quickly to meet the global challenge of COVID-19, by creating the capacity to help over 20 million patients monthly who may have been impacted by the pandemic with our testing products and our services and directly supporting healthcare professionals working on the front line to fight the virus. The Group has established widespread PCR testing capabilities and has carried out over 25 million tests in its own laboratories, is supporting the development of a number of vaccines and has established its SAFER@WORK™ testing, monitoring and consulting programmes to help ensure safer environments, travel and events during COVID-19.

Eurofins has grown very strongly since its inception and its strategy is to continue expanding its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions.

Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF FP).

*Until it has been lawfully made public widely by Eurofins through approved distribution channels, this document contains inside information for the purpose of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse, as amended.*

## Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific's management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company's management as of the date of publication, but no guarantees can be made as to their completeness or validity.